Obesity-associated mechanisms of hepatocarcinogenesis

Metabolism: Clinical and Experimental

Volumn 63, Issue 5, 2014, Pages 607-617

  Karagozian, Raffi ^a   Derdák, Zoltán ^b   Baffy, György ^c  

^a Department of Medicine Columbia University College of Physicians and Surgeons ^*  (United States)

^b BROWN UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adipose tissue remodeling; Hepatocellular carcinoma; Insulin resistance; Lipotoxicity; Nonalcoholic fatty liver disease

Indexed keywords

ADIPOCYTOKINE; INSULIN; SOMATOMEDIN;

ADIPOSE TISSUE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; DEVELOPED COUNTRY; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC REGULATION; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; LIPID STORAGE; LIPOTOXICITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; OBESITY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SENESCENCE; STELLATE CELL;

ADIPOSE TISSUE REMODELING; HEPATOCELLULAR CARCINOMA; INSULIN RESISTANCE; LIPOTOXICITY; NONALCOHOLIC FATTY LIVER DISEASE;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION MEDIATORS; INSULIN; LIVER NEOPLASMS; OBESITY; SOMATOMEDINS;

EID: 84899447215     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.01.011     Document Type: Review

References (152)

1. World Health Organization Obesity and overweight. Fact sheet no. 311 Accessed at http://www.who.int/mediacentre/factsheets/fs311/en/
2. K.C. Zalesin, B.A. Franklin, and W.M. Miller et al. Impact of obesity on cardiovascular disease Med Clin North Am 95 5 2011 919 937
3. Y.C. Wang, K. McPherson, and T. Marsh et al. Health and economic burden of the projected obesity trends in the USA and the UK Lancet 378 9793 2011 815 825
4. E.E. Calle, C. Rodriguez, and K. Walker-Thurmond et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 17 2003 1625 1638
5. A. Wolk, G. Gridley, and M. Svensson et al. A prospective study of obesity and cancer risk (Sweden) Cancer Causes Control 12 1 2001 13 21
6. H. Moller, A. Mellemgaard, and K. Lindvig et al. Obesity and cancer risk: a Danish record-linkage study Eur J Cancer 30A 3 1994 344 350
7. K. Basen-Engquist, and M. Chang Obesity and cancer risk: recent review and evidence Curr Oncol Rep 13 1 2011 71 76
8. A.G. Renehan, M. Tyson, and M. Egger et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies Lancet 371 9612 2008 569 578
9. A.R. Carmichael Obesity as a risk factor for development and poor prognosis of breast cancer BJOG 113 10 2006 1160 1166
10. T.K. Murphy, E.E. Calle, and C. Rodriguez et al. Body mass index and colon cancer mortality in a large prospective study Am J Epidemiol 152 9 2000 847 854
11. F.X. Bosch, J. Ribes, and M. Diaz et al. Primary liver cancer: worldwide incidence and trends Gastroenterology 127 5 Suppl. 1 2004 S5 S16
12. A. Jemal, F. Bray, and M.M. Center et al. Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
13. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
14. Z.J. Zhang, Z.J. Zheng, and R. Shi et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis J Clin Endocrinol Metab 97 7 2012 2347 2353
15. S.F. Altekruse, K.A. McGlynn, and M.E. Reichman Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 9 2009 1485 1491
16. F. Turati, R. Talamini, and C. Pelucchi et al. Metabolic syndrome and hepatocellular carcinoma risk Br J Cancer 108 1 2013 222 228
17. C. Samanic, W.H. Chow, and G. Gridley et al. Relation of body mass index to cancer risk in 362,552 Swedish men Cancer Causes Control 17 7 2006 901 909
18. W. Borena, S. Strohmaier, and A. Lukanova et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults Int J Cancer 131 1 2012 193 200
19. S. Schlesinger, K. Aleksandrova, and T. Pischon et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort Int J Cancer 132 3 2013 645 657
20. T.M. Welzel, B.I. Graubard, and S. Zeuzem et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database Hepatology 54 2 2011 463 471
21. P. Angulo Nonalcoholic fatty liver disease N Engl J Med 346 16 2002 1221 1231
22. J.A. Marrero, R.J. Fontana, and G.L. Su et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States Hepatology 36 6 2002 1349 1354
23. M. Ekstedt, L.E. Franzen, and U.L. Mathiesen et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 4 2006 865 873
24. S. Dam-Larsen, U. Becker, and M.B. Franzmann et al. Final results of a long-term, clinical follow-up in fatty liver patients Scand J Gastroenterol 44 10 2009 1236 1243
25. N. Rafiq, C. Bai, and Y. Fang et al. Long-term follow-up of patients with nonalcoholic fatty liver Clin Gastroenterol Hepatol 7 2 2009 234 238
26. T. Andersen, and C. Gluud Liver morphology in morbid obesity: a literature study Int J Obes 8 2 1984 97 106
27. S. Bellentani, and C. Tiribelli The spectrum of liver disease in the general population: lesson from the Dionysos study J Hepatol 35 4 2001 531 537
28. J.D. Browning, L.S. Szczepaniak, and R. Dobbins et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 6 2004 1387 1395
29. C.D. Byrne, R. Olufadi, and K.D. Bruce et al. Metabolic disturbances in non-alcoholic fatty liver disease Clin Sci (Lond) 116 7 2009 539 564
30. C.D. Williams, J. Stengel, and M.I. Asike et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 140 1 2011 124 131
31. G. Marchesini, M. Brizi, and A.M. Morselli-Labate et al. Association of nonalcoholic fatty liver disease with insulin resistance Am J Med 107 5 1999 450 455
32. A. Smedile, and E. Bugianesi Steatosis and hepatocellular carcinoma risk Eur Rev Med Pharmacol Sci 9 5 2005 291 293
33. J.M. Page, and S.A. Harrison NASH and HCC Clin Liver Dis 13 4 2009 631 647
34. G. Baffy, E.M. Brunt, and S.H. Caldwell Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace J Hepatol 56 2012 1384 1391
35. E. Hashimoto, and K. Tokushige Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic? Hepatol Res 42 1 2012 1 14
36. A.J. Sanyal, C. Banas, and C. Sargeant et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C Hepatology 43 4 2006 682 689
37. M.S. Ascha, I.A. Hanouneh, and R. Lopez et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis Hepatology 51 6 2010 1972 1978
38. S. Yatsuji, E. Hashimoto, and M. Tobari et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C J Gastroenterol Hepatol 24 2 2009 248 254
39. D.L. White, F. Kanwal, and H.B. El-Serag Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review Clin Gastroenterol Hepatol 10 12 2012 1342 e2 1359 e2
40. Y. Arase, M. Kobayashi, and F. Suzuki et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients Hepatol Res 42 3 2012 264 272
41. Y. Kawamura, Y. Arase, and K. Ikeda et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma Am J Gastroenterol 107 2 2012 253 261
42. U.C. Nzeako, Z.D. Goodman, and K.G. Ishak Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients Am J Clin Pathol 105 1 1996 65 75
43. S.P. Hussain, J. Schwank, and F. Staib et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer Oncogene 26 15 2007 2166 2176
44. M.C. Kew Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis Liver Int 23 6 2003 405 409
45. J.B. Rooks, H.W. Ory, and K.G. Ishak et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use JAMA 242 7 1979 644 648
46. J.H. Stoot, R.J. Coelen, and M.C. De Jong et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases HPB (Oxford) 12 8 2010 509 522
47. M.F. Madhoun, J. Fazili, and B.C. Bright et al. Hepatitis C prevalence in patients with hepatocellular carcinoma without cirrhosis Am J Med Sci 339 2 2010 169 173
48. M.M. Yeh, H.D. Daniel, and M. Torbenson Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers Mod Pathol 23 2 2010 276 283
49. G. Guzman, E.M. Brunt, and L.M. Petrovic et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 132 11 2008 1761 1766
50. V. Paradis, S. Zalinski, and E. Chelbi et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis Hepatology 49 3 2009 851 859
51. A.L. Chagas, L.O. Kikuchi, and C.P. Oliveira et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res 42 10 2009 958 962
52. J. Ertle, A. Dechene, and J.P. Sowa et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis Int J Cancer 128 10 2010 2436 2443
53. A. Sanyal, A. Poklepovic, and E. Moyneur et al. Population-based risk factors and resource utilization for HCC: US perspective Curr Med Res Opin 26 9 2010 2183 2191
54. R.N. Rahman, and J.A. Ibdah Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: a population based study Hepatology 56 4 (Suppl.) 2012 241A
55. S. Nair, A. Mason, and J. Eason et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36 1 2002 150 155
56. M.M. Hassan, L.Y. Hwang, and C.J. Hatten et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus Hepatology 36 5 2002 1206 1213
57. Y. Kawamura, Y. Arase, and K. Ikeda et al. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients Am J Med 123 10 2010 951 e1 956 e1
58. C.L. Chen, H.I. Yang, and W.S. Yang et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan Gastroenterology 135 1 2008 111 121
59. G. N'Kontchou, J. Paries, and M.T. Htar et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis Clin Gastroenterol Hepatol 4 8 2006 1062 1068
60. S.S. Thorgeirsson, and J.W. Grisham Molecular pathogenesis of human hepatocellular carcinoma Nat Genet 31 4 2002 339 346
61. P.A. Farazi, and R.A. DePinho Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 9 2006 674 687
62. S. Lee, H.J. Lee, and J.H. Kim et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis Am J Pathol 163 4 2003 1371 1378
63. Y. Kondo, Y. Kanai, and M. Sakamoto et al. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma Hepatology 32 5 2000 970 979
64. R.N. Aravalli, E.N. Cressman, and C.J. Steer Cellular and molecular mechanisms of hepatocellular carcinoma: an update Arch Toxicol 87 2 2013 227 247
65. D.Y. Zhang, and S.L. Friedman Fibrosis-dependent mechanisms of hepatocarcinogenesis Hepatology 56 2 2012 769 775
66. K. Breuhahn, and P. Schirmacher Signaling networks in human hepatocarcinogenesis - novel aspects and therapeutic options Prog Mol Biol Transl Sci 97 2010 251 277
67. H. Kitano Cancer as a robust system: implications for anticancer therapy Nat Rev Cancer 4 3 2004 227 235
68. D.M. Torres, and S.A. Harrison Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil Semin Liver Dis 32 1 2012 30 38
69. E.M. Brunt, D.E. Kleiner, and L.A. Wilson et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network Hepatology 49 3 2009 809 820
70. E.M. Brunt What's in a NAme? Hepatology 50 3 2009 663 667
71. Q.M. Anstee, A.K. Daly, and C.P. Day Genetics of alcoholic and nonalcoholic fatty liver disease Semin Liver Dis 31 2 2011 128 146
72. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 7 2007 2557 2576
73. D.W. Haslam, and W.P. James Obesity Lancet 366 9492 2005 1197 1209
74. S. Virtue, and A. Vidal-Puig Adipose tissue expandability, lipotoxicity and the metabolic syndrome - an allostatic perspective Biochim Biophys Acta 1801 3 2010 338 349
75. K. Sun, C.M. Kusminski, and P.E. Scherer Adipose tissue remodeling and obesity J Clin Invest 121 6 2011 2094 2101
76. S.E. Shoelson, L. Herrero, and A. Naaz Obesity, inflammation, and insulin resistance Gastroenterology 132 6 2007 2169 2180
77. G.S. Hotamisligil Inflammation and metabolic disorders Nature 444 7121 2006 860 867
78. Q. He, Z. Gao, and J. Yin et al. Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia Am J Physiol Endocrinol Metab 300 5 2011 E877 E885
79. F. Marra, and C. Bertolani Adipokines in liver diseases Hepatology 50 3 2009 957 969
80. F. Stickel, and C. Hellerbrand Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications Gut 59 10 2010 1303 1307
81. E.J. Park, J.H. Lee, and G.Y. Yu et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression Cell 140 2 2010 197 208
82. J. Shen, I. Sakaida, and K. Uchida et al. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells Life Sci 77 13 2005 1502 1515
83. S. Aleffi, I. Petrai, and C. Bertolani et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells Hepatology 42 6 2005 1339 1348
84. P. Angulo, L.M. Alba, and L.M. Petrovic et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease J Hepatol 41 6 2004 943 949
85. N.K. Saxena, D. Sharma, and X. Ding et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells Cancer Res 67 6 2007 2497 2507
86. M. Dalamaga, K.N. Diakopoulos, and C.S. Mantzoros The role of adiponectin in cancer: a review of current evidence Endocr Rev 33 4 2012 547 594
87. Z. Luo, A.K. Saha, and X. Xiang et al. AMPK, the metabolic syndrome and cancer Trends Pharmacol Sci 26 2 2005 69 76
88. T. Kadowaki, T. Yamauchi, and N. Kubota et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome J Clin Invest 116 7 2006 1784 1792
89. C. Postic, and J. Girard Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice J Clin Invest 118 3 2008 829 838
90. K.L. Donnelly, C.I. Smith, and S.J. Schwarzenberg et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J Clin Invest 115 5 2005 1343 1351
91. F. Diraison, and M. Beylot Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification Am J Physiol 274 2 Pt. 1 1998 E321 E327
92. I. Shimomura, M. Matsuda, and R.E. Hammer et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice Mol Cell 6 1 2000 77 86
93. P. Ferre, and F. Foufelle SREBP-1c transcription factor and lipid homeostasis: clinical perspective Horm Res 68 2 2007 72 82
94. M.A. Herman, O.D. Peroni, and J. Villoria et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism Nature 484 7394 2012 333 338
95. L. Eissing, T. Scherer, and K. Todter et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health Nat Commun 4 2013 1528
96. H. Yamashita, M. Takenoshita, and M. Sakurai et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver Proc Natl Acad Sci U S A 98 16 2001 9116 9121
97. T. Kabashima, T. Kawaguchi, and B.E. Wadzinski et al. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver Proc Natl Acad Sci U S A 100 9 2003 5107 5112
98. J.S. Lee, R. Mendez, and H.H. Heng et al. Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation Am J Transl Res 4 1 2012 102 113
99. R.H. Unger, G.O. Clark, and P.E. Scherer et al. Lipid homeostasis, lipotoxicity and the metabolic syndrome Biochim Biophys Acta 1801 3 2010 209 214
100. J. Wu, and R.J. Kaufman From acute ER stress to physiological roles of the unfolded protein response Cell Death Differ 13 3 2006 374 384
101. P. Puri, F. Mirshahi, and O. Cheung et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease Gastroenterology 134 2 2008 568 576
102. S.C. Cazanave, and G.J. Gores Mechanisms and clinical implications of hepatocyte lipoapoptosis Clin Lipidol 5 1 2010 71 85
103. U. Ozcan, Q. Cao, and E. Yilmaz et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes Science 306 5695 2004 457 461
104. M. Vinciguerra, F. Carrozzino, and M. Peyrou et al. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN J Hepatol 50 6 2009 1132 1141
105. S. Joshi-Barve, S.S. Barve, and K. Amancherla et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes Hepatology 46 3 2007 823 830
106. S.P. Hussain, L.J. Hofseth, and C.C. Harris Radical causes of cancer Nat Rev Cancer 3 4 2003 276 285
107. I.J. Lodhi, X. Wei, and C.F. Semenkovich Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter Trends Endocrinol Metab 22 1 2011 1 8
108. S.S. Choi, and A.M. Diehl Hepatic triglyceride synthesis and nonalcoholic fatty liver disease Curr Opin Lipidol 19 3 2008 295 300
109. H. Dong, and M.J. Czaja Regulation of lipid droplets by autophagy Trends Endocrinol Metab 22 6 2011 234 240
110. R. Singh, S. Kaushik, and Y. Wang et al. Autophagy regulates lipid metabolism Nature 458 7242 2009 1131 1135
111. A.R. Saltiel, and C.R. Kahn Insulin signalling and the regulation of glucose and lipid metabolism Nature 414 6865 2001 799 806
112. E.E. Calle, and R. Kaaks Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms Nat Rev Cancer 4 8 2004 579 591
113. M.S. Brown, and J.L. Goldstein Selective versus total insulin resistance: a pathogenic paradox Cell Metab 7 2 2008 95 96
114. M.J. Khandekar, P. Cohen, and B.M. Spiegelman Molecular mechanisms of cancer development in obesity Nat Rev Cancer 11 12 2011 886 895
115. K.W. Kim, S.K. Bae, and O.H. Lee et al. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma Cancer Res 58 2 1998 348 351
116. S. Tanaka, L. Mohr, and E.V. Schmidt et al. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes Hepatology 26 3 1997 598 604
117. V. Rottiers, and A.M. Naar MicroRNAs in metabolism and metabolic disorders Nat Rev Mol Cell Biol 13 4 2012 239 250
118. K.J. Moore, K.J. Rayner, and Y. Suarez et al. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism Annu Rev Nutr 31 2011 49 63
119. J. Lu, G. Getz, and E.A. Miska et al. MicroRNA expression profiles classify human cancers Nature 435 7043 2005 834 838
120. J.L. Mott MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia Hepatology 50 2 2009 630 637
121. S. Huang, and X. He The role of microRNAs in liver cancer progression Br J Cancer 104 2 2011 235 240
122. C. Augello, V. Vaira, and L. Caruso et al. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma Liver Int 32 5 2012 772 782
123. T. Fukuhara, and Y. Matsuura Role of miR-122 and lipid metabolism in HCV infection J Gastroenterol 48 2 2013 169 176
124. O. Cheung, P. Puri, and C. Eicken et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression Hepatology 48 6 2008 1810 1820
125. Z. Derdak, K.A. Villegas, and R. Harb et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease J Hepatol 58 4 2013 785 791
126. S. Cermelli, A. Ruggieri, and J.A. Marrero et al. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease PLoS One 6 8 2011 e23937
127. H. Hermeking p53 enters the microRNA world Cancer Cell 12 5 2007 414 418
128. M.L. Tornesello, L. Buonaguro, and F. Tatangelo et al. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections Genomics 102 2 2013 74 83
129. T. Li, N. Kon, and L. Jiang et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence Cell 149 6 2012 1269 1283
130. K. Bensaad, A. Tsuruta, and M.A. Selak et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis Cell 126 1 2006 107 120
131. S. Matoba, J.G. Kang, and W.D. Patino et al. p53 regulates mitochondrial respiration Science 312 5780 2006 1650 1653
132. Z. Derdak, C.H. Lang, and K.A. Villegas et al. Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease J Hepatol 54 1 2011 164 172
133. V. Stambolic, D. MacPherson, and D. Sas et al. Regulation of PTEN transcription by p53 Mol Cell 8 2 2001 317 325
134. R. Bataller, and D.A. Brenner Liver fibrosis J Clin Invest 115 2 2005 209 218
135. S.L. Friedman Mechanisms of hepatic fibrogenesis Gastroenterology 134 6 2008 1655 1669
136. V. Krizhanovsky, M. Yon, and R.A. Dickins et al. Senescence of activated stellate cells limits liver fibrosis Cell 134 4 2008 657 667
137. N. Ohtani, and E. Hara Roles and mechanisms of cellular senescence in regulation of tissue homeostasis Cancer Sci 104 5 2013 525 530
138. T. Tchkonia, Y. Zhu, and J. van Deursen et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities J Clin Invest 123 3 2013 966 972
139. S. Yoshimoto, T.M. Loo, and K. Atarashi et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome Nature 499 7456 2013 97 101
140. G. Brancatelli, M.P. Federle, and L. Grazioli et al. Hepatocellular carcinoma in noncirrhotic liver: CT, clinical, and pathologic findings in 39 U.S. residents Radiology 222 1 2002 89 94
141. Y.N. Park, C.P. Yang, and O. Cubukcu et al. Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis Liver 17 6 1997 271 274
142. P. Hytiroglou, Y.N. Park, and G. Krinsky et al. Hepatic precancerous lesions and small hepatocellular carcinoma Gastroenterol Clin North Am 36 4 2007 867 887 [vii]
143. D. Schuppan, and N.H. Afdhal Liver cirrhosis Lancet 371 9615 2008 838 851
144. L. Zhao The gut microbiota and obesity: from correlation to causality Nat Rev Microbiol 11 9 2013 639 647
145. G. Szabo, A. Dolganiuc, and P. Mandrekar Pattern recognition receptors: a contemporary view on liver diseases Hepatology 44 2 2006 287 298
146. S. Maeda, H. Kamata, and J.L. Luo et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis Cell 121 7 2005 977 990
147. D.H. Dapito, A. Mencin, and G.Y. Gwak et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4 Cancer Cell 21 4 2012 504 516
148. I.R. Wanless, and J.S. Lentz Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors Hepatology 12 5 1990 1106 1110
149. J.F. Silverman, K.F. O'Brien, and S. Long et al. Liver pathology in morbidly obese patients with and without diabetes Am J Gastroenterol 85 10 1990 1349 1355
150. C.A. Matteoni, Z.M. Younossi, and T. Gramlich et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 6 1999 1413 1419
151. M.J. Alter, D. Kruszon-Moran, and O.V. Nainan et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 8 1999 556 562
152. C. Niederau, S. Lange, and T. Heintges et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study Hepatology 28 6 1998 1687 1695